• Opinion
• [FOUCS] Fundamental issues with listed drug reevaluation
• by Kim, Jung-Ju Feb 13, 2020 06:27am

• Opinion
• [Reporter’s view]2019n-CoV & safety ignorance of companies
• by Kim, Jin-Gu Feb 12, 2020 06:27am

• Opinion
• All the access in China must be cut off
• by Nho, Byung Chul Feb 11, 2020 06:30am

• Opinion
• [Reporter’s View]Trust is essential to prevent a MERS II
• by Lee, Hye-Kyung Feb 5, 2020 02:22am

• Opinion
• [Reporter’s view]Dilemma of salesperson suicide & reporting
• by Eo, Yun-Ho Feb 3, 2020 06:23am

• Opinion
• [FOCUS] 10 ‘global new drugs’ promised 10 years ago
• by Chon, Seung-Hyun Jan 15, 2020 06:28am

• Opinion
• [FOCUS] Pharmaceutical bio-industry in the Middle of Change
• by Kim, Jung-Ju Jan 8, 2020 08:10pm

• Opinion
• [Reporter’s View] At least a guideline for ‘class effect’
• by Eo, Yun-Ho Jan 3, 2020 06:33am

• Opinion
• [Reporter’s View] Next year wishes for the industry
• by An, Kyung-Jin Dec 30, 2019 09:47pm

• Opinion
• [FOCUS] There is no reliability of cluless government policy
• by Chon, Seung-Hyun Dec 26, 2019 06:29am